Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Lymphir
(United States) [Available]Synonyms :
denileukin diftitox
Class :
Antineoplastic Agents and Biologic Response Modifiers
Brand Name :
Lymphir
(United States) [Available]Synonyms :
denileukin diftitox
Class :
Antineoplastic Agents and Biologic Response Modifiers
Dosage forms & strengths:  Â
Solution Â
150 mcg/mlÂ
Administer a dose of 9 mcg/kg once a day by IV infusion given over 30 to 60 minutes for five days up to every 21 days course in eight cycles
when both drugs are combined, there may be an increased risk and severity of life-threatening infections  
when both drugs are combined, there may be an increased risk and severity of life-threatening infections  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be an increased risk of adverse effects  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be a reduced response to the skin test 
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a decreased therapeutic effect of the vaccine  
when both drugs are combined, there may be a reduced response to the skin test 
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections  
when both drugs are combined, there may be an increased risk of serious infections
Frequency defined  Â
>10% Â
Capillary leak syndrome  Â
Hypotension  Â
Infusion reactions  Â
pyrexia  Â
rigors  Â
fatigue  Â
Nausea  Â
vomiting  Â
diarrhea    Â
1-10%  Â
Visual changes  Â
Black Box Warning:Â Â
The black box warning indicates the risk of capillary leak syndrome.Â
Contraindication/Caution:Â Â
None Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.Â
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.Â
Category N: There is no data available for the drug under this category.
Pharmacology:Â Â
Denileukin Diftitox specifically targets cells expressing the IL-2 receptor, which is expressed on certain types of cancer cells such as cutaneous T-cell lymphoma (CTCL) cells.  Â
Pharmacodynamics:Â Â
Limited information is available
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
It is administered via intravenous route i.e., into the vein. Â
Patient Information Leaflet  Â
Generic Name: Denileukin Diftitox  Â
Why do we use Denileukin Diftitox? Â
The IL2-receptor-directed cytotoxin denileukin is prescribed to treat Stage I to III cutaneous T-cell lymphoma (CTCL) that has relapsed or is resistant following at least one previous systemic therapy.Â
Adult patients with recurrent or chronic cutaneous T-cell lymphoma (CTCL) whose cancerous cells express the CD25 component of the IL-2 receptor treated with denileukin.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
